Fosfomycin-daptomycin and Other Fosfomycin Combinations As Alternative Therapies in Experimental Foreign-body Infection by Methicillin-resistant Staphylococcus Aureus

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2012 Oct 24

PMID 23089756

Citations 26

Authors

C Garrigos

O Murillo

J Lora-Tamayo

R Verdaguer

F Tubau

C Cabellos

J Cabo

J Ariza

Affiliations

Soon will be listed here.

Abstract

The efficacy of daptomycin, imipenem, or rifampin with fosfomycin was evaluated and compared with that of daptomycin-rifampin in a tissue cage model infection caused by methicillin-resistant Staphylococcus aureus (MRSA). Strain HUSA 304 was used. The study yielded the following results for MICs (in μg/ml): fosfomycin, 4; daptomycin, 1; imipenem, 0.25; and rifampin, 0.03. The study yielded the following results for minimum bactericidal concentration (MBC) (in μg/ml): fosfomycin, 8; daptomycin, 4; imipenem, 32; and rifampin, 0.5. Daptomycin-rifampin was confirmed as the most effective therapy against MRSA foreign-body infections. Fosfomycin combinations with high doses of daptomycin and rifampin were efficacious alternative therapies in this setting. Fosfomycin-imipenem was relatively ineffective and did not protect against resistance.

Citing Articles

Navigating the Current Treatment Landscape of Metallo-β-Lactamase-Producing Gram-Negative Infections: What are the Limitations?.

Grabein B, Arhin F, Daikos G, Moore L, Balaji V, Baillon-Plot N Infect Dis Ther. 2024; 13(11):2423-2447.

PMID: 39352652 PMC: 11499561. DOI: 10.1007/s40121-024-01044-8.

Efficacy of rifampicin combination therapy against MRSA prosthetic vascular graft infections in a rat model.

Johansen M, Petersen M, Faddy E, Seefeldt A, Mitkin A, Ostergaard L Biofilm. 2024; 7:100189.

PMID: 38481761 PMC: 10933452. DOI: 10.1016/j.bioflm.2024.100189.

In Silico and In Vitro Identification of 1,8-Dihydroxy-4,5-dinitroanthraquinone as a New Antibacterial Agent against and .

Amorim J, Vasquez V, Cabrera A, Martinez M, Carpio J Molecules. 2024; 29(1).

PMID: 38202786 PMC: 10779913. DOI: 10.3390/molecules29010203.

New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.

Oliva A, Cogliati Dezza F, Cancelli F, Curtolo A, Falletta A, Volpicelli L J Clin Med. 2023; 12(24).

PMID: 38137762 PMC: 10743892. DOI: 10.3390/jcm12247693.

Infective Endocarditis after Transcatheter Aortic Valve Replacement: Challenges in the Diagnosis and Management.

Zakhour J, Allaw F, Kalash S, Wehbe S, Kanj S Pathogens. 2023; 12(2).

PMID: 36839526 PMC: 9960284. DOI: 10.3390/pathogens12020255.

References

Debbia E, Pesce A, Schito G . In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria. Antimicrob Agents Chemother. 1988; 32(2):279-81. PMC: 172154. DOI: 10.1128/AAC.32.2.279. View

Portier H, Tremeaux J, Chavanet P, Gouyon J, Duez J, Kazmierczak A . Treatment of severe staphylococcal infections with cefotaxime and fosfomycin in combination. J Antimicrob Chemother. 1984; 14 Suppl B:277-84. DOI: 10.1093/jac/14.suppl_b.277. View

Garrigos C, Murillo O, Euba G, Verdaguer R, Tubau F, Cabellos C . Efficacy of tigecycline alone and with rifampin in foreign-body infection by methicillin-resistant Staphylococcus aureus. J Infect. 2011; 63(3):229-35. DOI: 10.1016/j.jinf.2011.07.001. View

Quentin C, Saivin S, Lafferriere C, Noury P, Bebear C . In vitro activity of fosfomycin combined with rifampin, pefloxacin and imipenem against staphylococci: a study by the time-kill curve method. Drugs Exp Clin Res. 1987; 13(4):219-24. View

Garrigos C, Murillo O, Lora-Tamayo J, Verdaguer R, Tubau F, Cabellos C . Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2012; 56(7):3806-11. PMC: 3393403. DOI: 10.1128/AAC.00127-12. View

Murillo O, Domenech A, Garcia A, Tubau F, Cabellos C, Gudiol F . Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2006; 50(12):4011-7. PMC: 1693998. DOI: 10.1128/AAC.00523-06. View

Roussos N, Karageorgopoulos D, Samonis G, Falagas M . Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents. 2009; 34(6):506-15. DOI: 10.1016/j.ijantimicag.2009.08.013. View

Zimmerli W, Frei R, Widmer A, Rajacic Z . Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother. 1994; 33(5):959-67. DOI: 10.1093/jac/33.5.959. View

Falagas M, Roussos N, Gkegkes I, Rafailidis P, Karageorgopoulos D . Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs. 2009; 18(7):921-44. DOI: 10.1517/13543780902967624. View

10.

Portier H, Kazmierczak A, Lucht F, Tremeaux J, Chavanet P, Duez J . Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections. Infection. 1985; 13 Suppl 1:S123-8. DOI: 10.1007/BF01644232. View

11.

Chen L, Huang C, Kuo S, Hsiao C, Lin M, Wang F . High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report. BMC Infect Dis. 2011; 11:152. PMC: 3119071. DOI: 10.1186/1471-2334-11-152. View

12.

Tang H, Chen C, Cheng K, Toh H, Su B, Chiang S . In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms. J Antimicrob Chemother. 2012; 67(4):944-50. DOI: 10.1093/jac/dkr535. View

13.

Quentin C, Noury P, Laurent C, Saivin S, Bebear C . [In vitro action of fosfomycin combined with rifampicin, pefloxacin and imipenem on staphylococci (checkerboard method in a liquid medium)]. Pathol Biol (Paris). 1987; 35(2):153-7. View

14.

Garrigos C, Murillo O, Euba G, Verdaguer R, Tubau F, Cabellos C . Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010; 54(12):5251-6. PMC: 2981248. DOI: 10.1128/AAC.00226-10. View

15.

Poeppl W, Tobudic S, Lingscheid T, Plasenzotti R, Kozakowski N, Georgopoulos A . Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010; 55(2):931-3. PMC: 3028784. DOI: 10.1128/AAC.00881-10. View

16.

Pachon-Ibanez M, Ribes S, Dominguez M, Fernandez R, Tubau F, Ariza J . Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin. Eur J Clin Microbiol Infect Dis. 2010; 30(1):89-95. DOI: 10.1007/s10096-010-1058-0. View

17.

John A, Baldoni D, Haschke M, Rentsch K, Schaerli P, Zimmerli W . Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother. 2009; 53(7):2719-24. PMC: 2704655. DOI: 10.1128/AAC.00047-09. View

18.

Poeppl W, Tobudic S, Lingscheid T, Plasenzotti R, Kozakowski N, Lagler H . Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Antimicrob Agents Chemother. 2011; 55(11):4999-5003. PMC: 3194995. DOI: 10.1128/AAC.00584-11. View

19.

Mascio C, Alder J, Silverman J . Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007; 51(12):4255-60. PMC: 2167999. DOI: 10.1128/AAC.00824-07. View

20.

Miro J, Entenza J, Del Rio A, Velasco M, Castaneda X, Garcia de la Maria C . High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2012; 56(8):4511-5. PMC: 3421550. DOI: 10.1128/AAC.06449-11. View